<DOC>
	<DOCNO>NCT02127866</DOCNO>
	<brief_summary>The purpose study determine optimal dose CHF 5259 ( glycopyrrolate bromide ) top Foster provide optimal additive bronchodilator effect asthmatic patient whose symptom uncontrolled medium dose inhaled corticosteroid plus long acting beta2 agonist .</brief_summary>
	<brief_title>Triple Asthma Dose Finding</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male female patient age &gt; =18 year Uncontrolled asthma medium dos ICS+LABA ACQ &gt; =1.5 Prebronchodilator FEV1 â‰¥40 % &lt; 80 % predict normal value Pregnant lactate woman Diagnosis COPD Patients treat asthma exacerbation 4 week prior study entry Patients therapy gastroesophageal reflux disease Patients clinically significant cardiovascular condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Asthma , anticholinergic</keyword>
</DOC>